AN2 Therapeutics Stock (NASDAQ:ANTX)

Forecast Revenue Ownership Financials Chart

Previous Close

$1.04

52W Range

$0.87 - $22.22

50D Avg

$1.88

200D Avg

$6.89

Market Cap

$31.04M

Avg Vol (3M)

$606.27K

Beta

-0.21

Div Yield

-

ANTX Company Profile

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

41

IPO Date

Mar 25, 2022

Website

ANTX Performance

ANTX Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	-	-	-
Operating Income	$-69.64M	$-42.26M	$-21.57M
Net Income	$-64.73M	$-41.47M	$-21.47M
EBITDA	$-69.64M	$-42.26M	$-21.57M
Basic EPS	-	$-2.70	$-1.18
Diluted EPS	-	$-2.70	$-1.18

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

Ticker	Company
PMVP	PMV Pharmaceuticals, Inc.
MLYS	Mineralys Therapeutics, Inc.
AVTE	Aerovate Therapeutics, Inc.
ACRV	Acrivon Therapeutics, Inc. Common Stock
MNOV	MediciNova, Inc.
PHVS	Pharvaris N.V.
RZLT	Rezolute, Inc.
PEPG	PepGen Inc.
ANEB	Anebulo Pharmaceuticals, Inc.
ADAG	Adagene Inc.
MOLN	Molecular Partners AG
ELYM	Eliem Therapeutics, Inc.